GILD Key Statistics, Chart & Performance
The current stock price of GILD is 125.27 USD. In the past month the price increased by 3.98%. In the past year, price increased by 35.31%.
GILD Latest News, Press Relases and Analysis
GILD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.79 | 14.01B |
Related stock screener links
About GILD
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404 US
CEO: Daniel P. O'Day
Employees: 17600
Phone: 16505743000
GILEAD SCIENCES INC / GILD FAQ
What does GILEAD SCIENCES INC do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of GILD is 125.27 USD. The price decreased by -1.08% in the last trading session.
What is the dividend status of GILEAD SCIENCES INC?
GILEAD SCIENCES INC (GILD) has a dividend yield of 2.53%. The yearly dividend amount is currently 3.14.
What is the ChartMill technical and fundamental rating of GILD stock?
GILD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is GILEAD SCIENCES INC (GILD) stock traded?
GILD stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of GILEAD SCIENCES INC (GILD)?
The PE ratio for GILEAD SCIENCES INC (GILD) is 15.3. This is based on the reported non-GAAP earnings per share of 8.19 and the current share price of 125.27 USD.
What is the market capitalization of GILD stock?
GILEAD SCIENCES INC (GILD) has a market capitalization of 155.44B USD. This makes GILD a Large Cap stock.
GILD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GILD. When comparing the yearly performance of all stocks, GILD is one of the better performing stocks in the market, outperforming 88.27% of all stocks.
GILD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GILD. GILD scores excellent on profitability, but there are some minor concerns on its financial health.
GILD Financial Highlights
Over the last trailing twelve months GILD reported a non-GAAP Earnings per Share(EPS) of 8.19. The EPS increased by 84.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
GILD Forecast & Estimates
36 analysts have analysed GILD and the average price target is 133.63 USD. This implies a price increase of 6.67% is expected in the next year compared to the current price of 125.27.
For the next year, analysts expect an EPS growth of 80.38% and a revenue growth 2.59% for GILD